The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60 to 74 at high risk ...

ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new ...

GSK’s 5-in-1 meningococcal vaccine Penmenvy receives positive recommendation from US Advisory Committee on Immunization Practices: London, UK Saturday, April 19, 2025, 13:00 Hrs ...

The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease. Individuals with underlying ...

THURSDAY, April 17, 2025 (HealthDay News) — A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including respiratory syncytial virus (RSV), ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

GSK plc has announced that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of RSV vaccines including GSK’s Arexvy (Respiratory Syncytial ...

GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in ...